Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay.

Kamelgarn M, Chen J, Kuang L, Jin H, Kasarskis EJ, Zhu H.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11904-E11913. doi: 10.1073/pnas.1810413115. Epub 2018 Nov 19.

2.

Self-Regulation and Executive Functioning as Related to Survival in Motor Neuron Disease: Preliminary Findings.

Garcia-Willingham NE, Roach AR, Kasarskis EJ, Segerstrom SC.

Psychosom Med. 2018 Sep;80(7):665-672. doi: 10.1097/PSY.0000000000000602.

PMID:
29771729
3.

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

Mehta P, Horton DK, Kasarskis EJ, Tessaro E, Eisenberg MS, Laird S, Iskander J.

MMWR Morb Mortal Wkly Rep. 2017 Dec 22;66(50):1379-1382. doi: 10.15585/mmwr.mm6650a3.

4.

Hydration measured by doubly labeled water in ALS and its effects on survival.

Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, Simmons Z, Tandan R; ALS Nutrition-NIPPV Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):220-231. doi: 10.1080/21678421.2017.1413117. Epub 2017 Dec 15.

PMID:
29243507
5.

Clinical and experimental studies of a novel P525R FUS mutation in amyotrophic lateral sclerosis.

Kuang L, Kamelgarn M, Arenas A, Gal J, Taylor D, Gong W, Brown M, St Clair D, Kasarskis EJ, Zhu H.

Neurol Genet. 2017 Jul 20;3(4):e172. doi: 10.1212/NXG.0000000000000172. eCollection 2017 Aug.

6.

Purpose in life in ALS patient-caregiver dyads: A multilevel longitudinal analysis.

Garcia NE, Morey JN, Kasarskis EJ, Segerstrom SC.

Health Psychol. 2017 Nov;36(11):1092-1104. doi: 10.1037/hea0000507. Epub 2017 May 25.

PMID:
28541074
7.

What lurks in the mind of someone with dysphagia?

Kasarskis EJ.

Muscle Nerve. 2017 Jul;56(1):2-3. doi: 10.1002/mus.25683. Epub 2017 Jun 5. No abstract available.

PMID:
28472864
8.

Fixed dynamometry is more sensitive than vital capacity or ALS rating scale.

Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, Haines T, English RA, Fetterman KA, Kasarskis EJ, Florence J, Simmons Z, Cudkowicz ME.

Muscle Nerve. 2017 Oct;56(4):710-715. doi: 10.1002/mus.25586. Epub 2017 Mar 21.

PMID:
28120413
9.

ALS mutant SOD1 interacts with G3BP1 and affects stress granule dynamics.

Gal J, Kuang L, Barnett KR, Zhu BZ, Shissler SC, Korotkov KV, Hayward LJ, Kasarskis EJ, Zhu H.

Acta Neuropathol. 2016 Oct;132(4):563-76. doi: 10.1007/s00401-016-1601-x. Epub 2016 Aug 1.

10.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

11.

Relationship of creatine kinase to body composition, disease state, and longevity in ALS.

Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Kryscio RJ, Bromberg MB.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):473-7. doi: 10.3109/21678421.2015.1062516. Epub 2015 Aug 27.

12.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

13.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.

14.

FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription.

Dhar SK, Zhang J, Gal J, Xu Y, Miao L, Lynn BC, Zhu H, Kasarskis EJ, St Clair DK.

Antioxid Redox Signal. 2014 Apr 1;20(10):1550-66. doi: 10.1089/ars.2012.4984. Epub 2013 Sep 20.

15.

Expressive disclosure to improve well-being in patients with amyotrophic lateral sclerosis: a randomised, controlled trial.

Averill AJ, Kasarskis EJ, Segerstrom SC.

Psychol Health. 2013;28(6):701-13. doi: 10.1080/08870446.2012.754891. Epub 2013 Jan 7.

16.

Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis.

Kasarskis EJ, Hodskins J, St Clair WH.

J Neurol Sci. 2011 Sep 15;308(1-2):155-7. doi: 10.1016/j.jns.2011.06.016. Epub 2011 Jul 2.

PMID:
21726879
17.

What does body mass index measure in amyotrophic lateral sclerosis and why should we care?

Kasarskis EJ.

Muscle Nerve. 2011 Jul;44(1):4-5. doi: 10.1002/mus.22113. Epub 2011 May 23. No abstract available.

PMID:
21607986
18.

The ALS Nutrition/NIPPV Study: design, feasibility, and initial results.

Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Amyotroph Lateral Scler. 2011 Jan;12(1):17-25. doi: 10.3109/17482968.2010.515225.

PMID:
21271789
19.

Neurological mortality among Gulf War veterans.

Horner RD, Feussner JR, Kasarskis EJ.

Am J Ind Med. 2010 May;53(5):548-9. doi: 10.1002/ajim.20809. No abstract available.

PMID:
20191602
20.

Factors associated with survival in the National Registry of Veterans with ALS.

Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, Morgenlander JC, Norman BB, Rozear MP, Sams LA, Sabet A, Bedlack RS.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):332-8. doi: 10.3109/17482960802320545.

PMID:
19922120
21.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4. Review.

22.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Review. Erratum in: Neurology. 2010 Mar 2;74(9):781. Neurology. 2009 Dec 15;73(24):2134.

23.

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group.

Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743.

24.

Myasthenia gravis associated with etanercept therapy.

Fee DB, Kasarskis EJ.

Muscle Nerve. 2009 Jun;39(6):866-70. doi: 10.1002/mus.21280.

PMID:
19373885
25.

The dynamics of quality of life in ALS patients and caregivers.

Roach AR, Averill AJ, Segerstrom SC, Kasarskis EJ.

Ann Behav Med. 2009 Apr;37(2):197-206. doi: 10.1007/s12160-009-9092-9. Epub 2009 Apr 7.

PMID:
19350337
26.

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.

Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr.

Science. 2009 Feb 27;323(5918):1205-8. doi: 10.1126/science.1166066.

27.

Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis.

Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, Norman BB, Oddone EZ, Rozear MP, Sabet A, Sams L, Bedlack RS.

Amyotroph Lateral Scler. 2010;11(1-2):125-32. doi: 10.3109/17482960802572681.

PMID:
19153849
28.

Mutations in the SOD2 promoter reveal a molecular basis for an activating protein 2-dependent dysregulation of manganese superoxide dismutase expression in cancer cells.

Xu Y, Fang F, Dhar SK, Bosch A, St Clair WH, Kasarskis EJ, St Clair DK.

Mol Cancer Res. 2008 Dec;6(12):1881-93. doi: 10.1158/1541-7786.MCR-08-0253.

29.

Clinical aspects of ALS in Gulf War veterans.

Kasarskis EJ, Lindquist JH, Coffman CJ, Grambow SC, Feussner JR, Allen KD, Oddone EZ, Kamins KA, Horner RD; Als Gulf War Clinical Review Team.

Amyotroph Lateral Scler. 2009 Feb;10(1):35-41. doi: 10.1080/17482960802351029.

PMID:
18792848
30.

Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak.

Horner RD, Grambow SC, Coffman CJ, Lindquist JH, Oddone EZ, Allen KD, Kasarskis EJ.

Neuroepidemiology. 2008;31(1):28-32. doi: 10.1159/000136648. Epub 2008 Jun 6.

PMID:
18535397
31.

Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.

Schmidt S, Allen KD, Loiacono VT, Norman B, Stanwyck CL, Nord KM, Williams CD, Kasarskis EJ, Kamel F, McGuire V, Nelson LM, Oddone EZ.

Neuroepidemiology. 2008;30(3):191-204. doi: 10.1159/000126911. Epub 2008 Apr 18.

32.

The National Registry of Veterans with amyotrophic lateral sclerosis.

Allen KD, Kasarskis EJ, Bedlack RS, Rozear MP, Morgenlander JC, Sabet A, Sams L, Lindquist JH, Harrelson ML, Coffman CJ, Oddone EZ.

Neuroepidemiology. 2008;30(3):180-90. doi: 10.1159/000126910. Epub 2008 Apr 18.

PMID:
18421218
33.

Retrograde axonal transport and motor neuron disease.

Ström AL, Gal J, Shi P, Kasarskis EJ, Hayward LJ, Zhu H.

J Neurochem. 2008 Jul;106(2):495-505. doi: 10.1111/j.1471-4159.2008.05393.x. Epub 2008 Apr 1. Review.

34.

Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery.

Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH Jr, Cudkowicz M, Gordon PH, Hardy J, Kasarskis EJ, Kaufmann P, Miller R, Sorenson E, Tandan R, Traynor BJ, Nash J, Sherman A, Mailman MD, Ostell J, Bruijn L, Cwik V, Rich SS, Singleton A, Refolo L, Andrews J, Zhang R, Conwit R, Keller MA; ALS Research Group.

PLoS One. 2007 Dec 5;2(12):e1254.

35.

Psychological health in patients with amyotrophic lateral sclerosis.

Averill AJ, Kasarskis EJ, Segerstrom SC.

Amyotroph Lateral Scler. 2007 Aug;8(4):243-54. Review.

PMID:
17653923
36.

The role of a single-stranded nucleotide loop in transcriptional regulation of the human sod2 gene.

Xu Y, Fang F, Dhar SK, St Clair WH, Kasarskis EJ, St Clair DK.

J Biol Chem. 2007 Jun 1;282(22):15981-94. Epub 2007 Apr 9.

37.

Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.

Langmore SE, Kasarskis EJ, Manca ML, Olney RK.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004030. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD004030.

PMID:
17054194
38.

Promoting excellence in end-of-life care in ALS.

Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M, Miller RG, Appel SH, Benditt J, Bernat JL, Borasio GD, Carver AC, Clawson L, Del Bene ML, Kasarskis EJ, LeGrand SB, Mandler R, McCarthy J, Munsat T, Newman D, Sufit RL, Versenyi A.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Sep;6(3):145-54. Review.

PMID:
16183556
39.

Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R.

Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Mar;6(1):50-4.

PMID:
16036426
40.

Prospective study of military service and mortality from ALS.

Horner RD, Feussner JR, Kasarskis EJ.

Neurology. 2005 Jul 12;65(1):180-1; author reply 180-1. No abstract available.

PMID:
16009927
41.

Occurrence of amyotrophic lateral sclerosis among Gulf War veterans.

Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y, Mitsumoto H, Pascuzzi R, Spencer PS, Tim R, Howard D, Smith TC, Ryan MA, Coffman CJ, Kasarskis EJ.

Neurology. 2003 Sep 23;61(6):742-9. Review. Erratum in: Neurology. 2003 Nov 11;61(9):1320.

PMID:
14504315
42.

Amyotrophic lateral sclerosis and hopelessness: psychosocial factors.

Plahuta JM, McCulloch BJ, Kasarskis EJ, Ross MA, Walter RA, McDonald ER.

Soc Sci Med. 2002 Dec;55(12):2131-40.

PMID:
12409126
43.

Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappaB dimerization.

Daosukho C, Kiningham K, Kasarskis EJ, Ittarat W, St Clair DK.

Oncogene. 2002 May 16;21(22):3603-10.

44.

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM.

J Neurol Sci. 1999 Oct 31;169(1-2):118-25.

PMID:
10540019
45.

An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta.

Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, St Clair DK.

DNA Cell Biol. 1999 Sep;18(9):709-22.

PMID:
10492402
46.

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review).

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Muscle Nerve. 1999 Aug;22(8):1104-18. No abstract available.

PMID:
10417794
47.

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Neurology. 1999 Apr 22;52(7):1311-23. No abstract available.

PMID:
10227612
48.

Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells.

Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK.

Oncogene. 1999 Jan 7;18(1):93-102.

49.

Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective.

Silani V, Kasarskis EJ, Yanagisawa N.

J Neurol. 1998 Aug;245 Suppl 2:S13-9; discussion S29. Review.

PMID:
9747929
50.

Distribution of MnSOD polymorphisms in sporadic ALS patients.

Tomblyn M, Kasarskis EJ, Xu Y, St Clair DK.

J Mol Neurosci. 1998 Feb;10(1):65-6. No abstract available.

PMID:
9589371

Supplemental Content

Loading ...
Support Center